Cat. #161681
SAR-22-097F mouse line
Cat. #: 161681
Disease: Non-alcoholic fatty liver disease (NAFLD)
Model: Knock-In
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Devanand Sarkar
Institute: Virginia Commonwealth University
Primary Citation: Komaniecki et al. Biochemistry 62(2):543-553. PMID: 36548985
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: SAR-22-097F mouse line
- Cancer: Carcinoma
- Research fields: Cancer
- Disease: Non-alcoholic fatty liver disease (NAFLD)
- Model: Knock-In
- Crispr: Yes
- Conditional: No
- Description: Mouse line with cysteine 75 of AEG-1 mutated to serine. AEG-1-C75S mice might be more prone to developing NASH and HCC which could help design new therapeutic strategies. Findings identify a novel role of AEG-1 palmitoylation regulating NASH and HCC thereby establishing the rationale for using inhibitors of AEG-1 depalmitoylating enzymes for the treatment of NASH and HCC.
- Application: RNA-Seq, Western Blot, and Immunofluorescence
- Genetic background: AEG-1-C75S mice were created in C57BL/6/J background. ATG-1-C75S heterozygotexheterozygote mating was performed to generate AEG-1-WT adn AEG-1-C75S littermates
- Phenotype: Unaffected litter size of AEG-1-C75S mice compared to WT adn overall showing milder and different phenotype compared to AEG-1-/- mice
- Strain: C57BL/6/J
- Production details: Knock-in mice by CRISPR/Cas9 in which Cys75 of AEG-1 was mutated to Ser (AEG-1-C75S). AEG-1-C75S mice were created in C57BL/6/J background. ATG-1-C75S heterozygotexheterozygote mating was performed to generate AEG-1-WT adn AEG-1-C75S littermates
- Recommended controls: AEG-1 WT
Application Details
- Application: RNA-Seq, Western Blot, and Immunofluorescence
References
- Komaniecki et al. Biochemistry 62(2):543-553. PMID: 36548985
